PMID- 31978895
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20210111
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jan 24
TI  - AR-induced ZEB1-AS1 represents poor prognosis in cholangiocarcinoma and 
      facilitates tumor stemness, proliferation and invasion through mediating 
      miR-133b/HOXB8.
PG  - 1237-1255
LID - 10.18632/aging.102680 [doi]
AB  - Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) has displayed vital 
      regulatory function in various tumors. However, the biological function of 
      ZEB1-AS1 in cholangiocarcinoma (CCA) remains unclear. In this study, we confirmed 
      that ZEB1-AS1 expression was increased in CCA tissues and cells, respectively. 
      Upregulated ZEB1-AS1 was related to lymph node invasion, advanced TNM stage and 
      poor survival of CCA patients. ZEB1-AS1 exhibited high sensitivity and 
      specificity to be an independent poor prognostic factor of patients with CCA. 
      Functionally, knocking down ZEB1-AS1 attenuated tumor cell stemness, restrained 
      cellular viability in vitro and in vivo, and inhibited CCA cell migration and 
      invasion by reversing epithelial-mesenchymal transition. For the mechanism, 
      androgen receptor (AR) directly promoted ZEB1-AS1 expression, and further 
      ZEB1-AS1 increased oncogene homeobox B8 (HOXB8) by sponging miR-133b. In 
      addition, malignant phenotypes of CCA promoted by ZEB1-AS1 dysregulation were 
      rescued separately through interfering miR-133b and HOXB8, suggesting 
      AR/ZEB1-AS1/miR-133b/HOXB8 exerted crucial functions in tumorigenesis and 
      progression of CCA.
FAU - Jiang, Xingming
AU  - Jiang X
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Li, Jinglin
AU  - Li J
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Wang, Weina
AU  - Wang W
AD  - Department of Anesthesiology, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Hu, Zengtao
AU  - Hu Z
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Guan, Canghai
AU  - Guan C
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Zhao, Yuqiao
AU  - Zhao Y
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Li, Wenzhi
AU  - Li W
AD  - Department of Anesthesiology, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
FAU - Cui, Yunfu
AU  - Cui Y
AD  - Department of General Surgery, Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200124
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
RN  - 0 (AR protein, human)
RN  - 0 (HOXB8 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (MIRN133 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Receptors, Androgen)
SB  - IM
MH  - Bile Duct Neoplasms/*etiology/*metabolism/mortality/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation
MH  - Cell Survival/genetics
MH  - Cell Transformation, Neoplastic/genetics/metabolism
MH  - Cholangiocarcinoma/*etiology/*metabolism/mortality/pathology
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplastic Stem Cells/metabolism
MH  - Prognosis
MH  - RNA Interference
MH  - RNA, Long Noncoding/*genetics
MH  - ROC Curve
MH  - Receptors, Androgen/*metabolism
MH  - Signal Transduction
PMC - PMC7053610
OTO - NOTNLM
OT  - HOXB8
OT  - ZEB1-AS1
OT  - cholangiocarcinoma
OT  - miR-133b
OT  - prognosis
COIS- CONFLICTS OF INTEREST: The authors declare no conflicts of interest.
EDAT- 2020/01/25 06:00
MHDA- 2021/01/12 06:00
PMCR- 2020/01/31
CRDT- 2020/01/25 06:00
PHST- 2019/10/04 00:00 [received]
PHST- 2019/12/25 00:00 [accepted]
PHST- 2020/01/25 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/01/25 06:00 [entrez]
PHST- 2020/01/31 00:00 [pmc-release]
AID - 102680 [pii]
AID - 10.18632/aging.102680 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2020 Jan 24;12(2):1237-1255. doi: 10.18632/aging.102680. Epub 
      2020 Jan 24.